Abstract Number: 1175 • ACR Convergence 2023
Inclusion of All Myositis Specific Autoantibodies or Other Rashes Leads to Better Sensitivity but Lower Specificity of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM), collectively known as myositis, are heterogeneous disorders characterized by muscle weakness and muscle inflammation. ACR/EULAR classification criterion for IIM was…Abstract Number: 1951 • ACR Convergence 2023
Valid and Reliable Physical Function Tests in Idiopathic Inflammatory Myositis
Background/Purpose: Idiopathic inflammatory myopathies (IIM) can cause significant impairment in physical function. Sit to Stand (STS) and Timed Up and Go (TUG) are quick and…Abstract Number: 0300 • ACR Convergence 2023
Nailfold Videocapillaroscopy in Idiopathic Inflammatory Myopathy Compared with Healthy Controls
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a group of autoimmune disorders that cause inflammation of the muscle. This includes dermatomyositis and polymyositis. Literature has been…Abstract Number: 1176 • ACR Convergence 2023
Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
Background/Purpose: Dermatomyositis (DM), an idiopathic inflammatory myopathy, is a chronic and often debilitating condition characterized by a hallmark skin rash (e.g., Gottron's sign and heliotrope…Abstract Number: 1952 • ACR Convergence 2023
Anti-MDA5 Associated Dermatomyositis: Clinical Features and Outcomes in a Predominantly African-American Case Series
Background/Purpose: Individuals with autoantibodies against melanoma differentiation-associated protein 5 (MDA-5) are reported to have a significant risk of developing rapidly progressive and fatal interstitial lung…Abstract Number: 028 • 2023 Pediatric Rheumatology Symposium
Achieving Medication-Free Remission in Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis. Systemic immunosuppression is needed. Evidence is limited…Abstract Number: 064 • 2023 Pediatric Rheumatology Symposium
Towards the Development of Composite Parent-Centered Disease Activity Scores for Juvenile Dermatomyositis
Background/Purpose: Increasing attention has been recently paid to the development of parent- and child-centered composite DAS for the assessment of health status of children with…Abstract Number: 066 • 2023 Pediatric Rheumatology Symposium
Telemedicine Use in the Assessment of Juvenile Myositis: A Mixed-Methods Study of an International Healthcare Provider Experience
Background/Purpose: Care of patients with juvenile myositis (JM) involves complex assessments performed by specialized healthcare providers (HCPs). Restrictions during the COVID-19 pandemic required the rapid…Abstract Number: 070 • 2023 Pediatric Rheumatology Symposium
The Impact of the COVID-19 Pandemic on Patients with Juvenile Idiopathic Inflammatory Myopathies
Background/Purpose: Since the onset of the COVID-19 pandemic, there have been concerns regarding the risks of SARS-CoV-2 infection in patients with juvenile idiopathic inflammatory myopathies…Abstract Number: 086 • 2023 Pediatric Rheumatology Symposium
Systemic Sclerosis Overlap Syndrome: A Case Series from a Single Large Pediatric Center
Background/Purpose: Childhood-onset systemic sclerosis (SSc) is a rare but potentially life-threatening autoimmune condition with features including immune, fibrotic, and vascular manifestations affecting the skin and…Abstract Number: 099 • 2023 Pediatric Rheumatology Symposium
The Impact of the COVID-19 Pandemic on Juvenile Dermatomyositis
Background/Purpose: Juvenile Dermatomyositis (JDM) is theorized to occur in a genetically susceptible individual as a response to an environmental trigger, leading to autoimmunity and inflammation.…Abstract Number: 100 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): II – A Longitudinal Assessment of Muscle Strength by Manual Muscle Test (MMT) and Childhood Myositis Assessment Scale (CMAS) Tools
Background/Purpose: Muscle weakness is often progressive and persistent in Juvenile Dermatomyositis (JDM). Muscle strength testing is useful for evaluating severity of muscle weakness. There is…Abstract Number: 101 • 2023 Pediatric Rheumatology Symposium
Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity
Background/Purpose: Previous studies in juvenile dermatomyositis (JDM) have shown that patients from minoritized ethnicities and those with lower family income are more likely to have…Abstract Number: 120 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up
Background/Purpose: A national registry was set up, enrolling new onset JDM cases in 18 hospitals, during 3-years (2015-2018) with 2-years follow up, in a low…Abstract Number: 004 • 2023 Pediatric Rheumatology Symposium
Analysis of Patients with Juvenile Dermatomyositis Compared to Healthy Controls Using CITE-seq Identifies Differences in Cell Composition and Gene and Epitope Expression
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare and serious systemic autoimmune condition, and much remains unknown about the pathogenesis, the immune cell types and cell-specific…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 24
- Next Page »